1. D. J. Rader and S. M. Haffner. Roles of fibrates in the management of hypertriglyceridemia. Am. J. Cardiol. 83:30F–35F (1999).
2. A. Lozada and C. A. Dujovne Drug interactions with fibric acids. Pharmacol. Ther. 63:163–176 (1994).
3. D. B. Miller and J. D. Spence. Clinical pharmacokinetics of fibric acid derivatives (Fibrates). Clin. Pharmacokinet. 34:155–162 (1998).
4. J. T. Backman, C. Kyrklund, K. T. Kivistö, J.-S. Wang, and P. J. Neuvonen. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68:122–129 (2000).
5. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila, and P. J. Neuvonen. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69:340–345 (2001).
6. J. T. Backman, C. Kyrklund, M. Neuvonen, and P. J. Neuvonen. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72:685–691 (2002).
7. C. Kyrklund, J. T. Backman, M. Neuvonen, and P. J. Neuvonen. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 73:538–544 (2003).
8. T. Prueksaritanont, J. Zhao, and B. Ma. Mechanistic studies on the metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. 301:1042–1051 (2002).
9. T. Prueksaritanont, C. Tang, Y. Qiu, L. Mu, R. Subramanain, and J. H. Lin. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30:1280–1287 (2002).
10. T. Prueksaritanont, L. M. Gorham, and B. Ma. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. 25:1191–1199 (1997).
11. J. A. Farmer. Learning from the cerivastatin experience. Lancet 358
12. K. Rašlová, D. Dubovská, V. Mongiellová, and T. Trnovec. Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia. Eur. J. Clin. Pharmacol. 52:101–106 (1997).
13. J. Sahi M. A. Milad, and X. Zheng. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J. Pharmacol. Exp. Ther. 306:1027–1034 (2003).
14. J. Sahi, C. B. Black, and G. A. Hamilton. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab. Dispos. 31:439–446 (2003).
15. D. J. Greenblatt, L. L. von-Moltke, J. P. Daily, J. S. Harmatz, and R. I. Shader. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J. Clin. Psychopharmacol. 19:293–296 (1999).
16. M. Pfister, L. Labbe, J. F. Lu, S. M. Hammer, J. Mellors, K. K. Bennett, S. Rosenkranz, L. B. Sheiner, and AIDS Clinical Trial Group Protocol 398 Investigators. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin. Pharmacol. Ther. 72:133–141 (2002).
17. Y. H. Wen, J. Sahi, and E. Urda. Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes. Drug Metab. Dispos. 30:977–984 (2002).
18. J. K. Ritter, F. K. Kessler, M. T. Thompson, A. D. Grove, D. J. Auyeung, and R. A. Fisher. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology 30:476–484 (1999).
19. G. Luo, M. Cunningham, and S. Kim. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30:795–804 (2002).
20. S. Gerbal-Chaloin, J.-M. Pascussi, L. Pichard-Garcia, M. Daujat, F. Waechter, J. M. Fabre, N. Carrere, and P. Maurel. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. 29:242–251 (2001).
21. T. Prueksaritanont, R. Subramanian, and X. Fang. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30:505–512 (2001).
22. Physician’s Desk Reference. Thompson PDR, New Jersey, 2003, pp. 759.
23. B. Blumberg, W. Sabbaagh, H. Juguilon, J. Bolado, C. van Meter, E. Ong, and R. Evan. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Gene Dev 12:3195–3205 (1998).
24. J. Lehmann, D. McKee, M. Watson, T. Wilson, J. Moore, and S. Kliewer. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Investig 102:1016–1023 (1998).
25. J. Sugatani, K. Yamakawa, and E. Tonda. The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem. Pharmacol. 67:989–1000 (2004).
26. D. P. Hartley, X. Dai, and Y. D. He. Activators of rat PXR differentially modulate hepatic and intestinal gene expression. Mol. Pharmacol. 65:1159–1171 (2004).
27. T. Walle, Y. Otake, A. Galijatovic, J. K. Ritter, and U. K. Walle. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line Hep G2. Drug Metab. Dispos. 28:1077–1082 (2000).
28. M. D. Green, C. D. King, B. Mojarrabi, P. I. Mackenzie, and T. R. Tephly. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab. Dispos. 26:507–512 (1998).
29. X.-Q. Li, A. Björkman, T. B. Anderson, M. Ridderström, and C. M. Masimirembwa. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300:399–407 (2002).
30. A. Galijatovic. U. K. Walle, and T. Walle. Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica 29:1241–1256 (1999).
31. B. Goodwin, E. Hodgson, and C. Liddle. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampin through a distal enhancer module. Mol. Pharmacol. 56:1329–1339 (1999).
32. L. Richert, C. Lamboley, and C. Viollon-Abadie. Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol. Appl. Pharmacol. 191:130–146 (2003).
33. M. G. Soars, D. M. Petullo, J. A. Eckstein, S. C. Kasper, and S. A. Wrighton. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab. Dispos. 32:140–148 (2004).
34. V. Meunier, M. Bourrié, B. Julian, E. Marti, F. Guillou, Y. Berger, and G. Fabre. Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica 30:589–607 (2000).
35. A. J. Bergman, G. Murphy, J. Burke, J. J. Zhao, R. Valesky, L. Liu, K. C. Lasseter, W. He, T. Prueksaritanont, Y. Qiu, A. Hartford, J. M. Vega, and J. F. Paolini. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J. Clin. Pharmacol. 44:1054–1062 (2004).
36. P. Mathew, T. Cuddy, W. G. Tracewell, and D. Salazar. An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin. Pharmacol. Ther. 75:33 (2004).
37. H. Fujino, I. Yamada, S. Shimada, M. Yoneda, and J. Kojima. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 33:27–41 (2003).
38. T. Prueksaritanont, B. Ma, and N. Yu. Human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, not CYP2D6. Br. J. Clin. Pharmacol. 56:120–124 (2003).
39. J. Y. Park, K. A. Kim, M. H. Kang, S. L. Kim, and J. G. Shin. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin. Pharmacol. Ther. 75:157–162 (2004).
40. Z. Dvořák k, M. Modrianský, and L. Pichard-Garcia. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol. Pharmacol. 64:160–169 (2003).